This publication was sponsored and written in partnership with Bristol-Myers Squibb. The American Journal of Managed Care ®: What are some specific patient characteristics associated with ...

Most disability accumulation in relapsing multiple sclerosis (MS) is not associated with overt relapses, challenging the current clinical distinction of relapsing and progressive forms of the disease, ...

The goal of this double-blind, adaptive, dose-ranging, phase 2 study was to assess safety, tolerability and dose-response characteristics of siponimod and its effects on brain MRI lesion activity in ...

Teva Canada and Novartis Canada are collaborating to ensure continued access to Mayzent for people with active SPMS in Canada ...

Multiple sclerosis (MS) is a rare and unpredictable autoimmune disease in which the body’s innate immune system attacks cells of the nervous system and breaks down the communication between nerve ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Results from the EVOLVE-MS-1 study show Vumerity was ...

Please provide your email address to receive an email when new articles are posted on . No new safety signals or serious adverse events were reported. Of 124 participants who received tolebrutinib 60 ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

A trial found six weeks of yoga improved sleep quality and reduced fatigue in people with MS, suggesting its use as a ...

Women are less likely than men to receive drugs for multiple sclerosis (MS) between the ages of 18 to 40, during women's childbearing years, even when those drugs have been shown to be safe for use ...

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis (MS) have the relapsing-remitting (RR) disease course. This means that people have relapses -- also ...

Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and autoimmune diseases. New research from the USC Schaeffer Center shows how ...